Henry Schein, Inc. (HSIC) vs ImmunityBio, Inc. (IBRX)

A side-by-side comparison of Henry Schein, Inc. and ImmunityBio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Henry Schein, Inc. logo
HSIC
Henry Schein, Inc.
$9.67B
$84.87HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
ImmunityBio, Inc. logo
IBRX
ImmunityBio, Inc.
$10.38B
$9.91HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT

Total return — HSIC vs IBRX

growth of $100 · dividends reinvested · last 10y
HSIC +31.1% (+2.7%/yr)IBRX +41.8% (+3.6%/yr)IBRX compounded faster over this window
0100200300400500Start $10020182020202220242026$131$142
HSIC IBRX

HSIC vs IBRX: by the numbers

  • •IBRX is the larger company ($10.38B vs $9.67B market cap).
  • •HSIC is profitable (2.96% net margin) while IBRX runs a net loss (-598.56%).
  • •IBRX grew revenue faster over the past five years (202.97% vs 2.71% CAGR).

Metrics side by side

Valuation

MetricHSICIBRX
P/E ratio24.74N/A
Forward P/E15.76N/A
PEG ratio7.83N/A
P/S ratio0.7162.60
P/B ratio3.06N/A
EV / EBITDA12.26N/A
FCF yield5.57%N/A

Profitability

MetricHSICIBRX
Gross margin30.31%94.63%
Operating margin5.69%-226.00%
Net margin2.96%-598.56%
ROE12.77%N/A
ROIC6.53%-45.63%

Growth (annualized)

MetricHSICIBRX
Revenue CAGR (5Y)2.71%202.97%
EPS CAGR (5Y)3.14%N/A
FCF CAGR (5Y)0.82%N/A
Total return CAGR (5Y)1.39%0.39%

Frequently asked

Which has grown faster, HSIC or IBRX?
Over the past five years, IBRX grew revenue faster — HSIC at a 2.71% CAGR versus IBRX at 202.97%.
Is HSIC or IBRX more profitable?
HSIC runs the higher net margin — HSIC at 2.96% versus IBRX at -598.56%.

Go deeper

Full HSIC analysisFull IBRX analysisInteractive comparison tool

Dig into the metrics

Henry Schein P/E ratioHenry Schein ROEImmunityBio ROEHenry Schein operating marginImmunityBio operating marginHenry Schein revenue growthImmunityBio revenue growthHenry Schein free cash flowImmunityBio free cash flow

Henry Schein & ImmunityBio appear in these rankings

Fastest Revenue Growth StocksHighest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.